The Emergency Bio-Solution Pharmaceutical Plant in Baltimore on April 1 revealed the need to replace the raw material as one of the manufacturer’s exports failed quality control.
The government feared that the incident would undermine confidence in the two vaccines, so it decided that from now on only US J&J vaccines would be produced there. British-Swedish company AstroGeneca is in talks with the US government to find new productivity.
Unlike the vaccine, which was jointly developed by Astrogeneca and the University of Oxford, the Jansen vaccine contains a single dose and has been approved for third emergency use in the United States. Vaccination of Astrogenogen has not yet been approved.
Cover image source: Rafael Henrik / Sofa Images / Light Rocket via Getty Images
“Internet evangelist. Writer. Hardcore alcoholaholic. Tv lover. Extreme reader. Coffee junkie. Falls down a lot.”